REGN14284
/ Regeneron
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
July 27, 2023
A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=48 | Completed | Sponsor: Regeneron Pharmaceuticals | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
January 17, 2023
A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=48 | Active, not recruiting | Sponsor: Regeneron Pharmaceuticals | Recruiting ➔ Active, not recruiting | N=136 ➔ 48
Enrollment change • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
October 17, 2022
A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=136 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
August 17, 2022
A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=136 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals
New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 4
Of
4
Go to page
1